TWD 70.5
(0.14%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 236.83 Million TWD | 4.59% |
2022 | 226.43 Million TWD | 15.83% |
2021 | 195.49 Million TWD | 38.36% |
2020 | 141.28 Million TWD | -15.71% |
2019 | 167.62 Million TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 76.73 Million TWD | 14.94% |
2024 Q1 | 66.75 Million TWD | 3.2% |
2023 Q4 | 64.68 Million TWD | 8.85% |
2023 FY | 236.83 Million TWD | 4.59% |
2023 Q3 | 59.42 Million TWD | 0.6% |
2023 Q2 | 59.07 Million TWD | 10.13% |
2023 Q1 | 53.64 Million TWD | -10.4% |
2022 FY | 226.43 Million TWD | 15.83% |
2022 Q4 | 59.86 Million TWD | 0.0% |
2021 FY | 195.49 Million TWD | 38.36% |
2020 FY | 141.28 Million TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
BIONET Corp. | 638.27 Million TWD | 62.895% |
DIVA Laboratories, Ltd. | 250.77 Million TWD | 5.56% |
Welgene Biotech Co.,Ltd. | 119.71 Million TWD | -97.827% |
Puriblood Medical Co., Ltd. | 6.52 Million TWD | -3530.691% |
TFBS Bioscience Inc. | 77.82 Million TWD | -204.295% |